{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=CYP+substrates", "query": { "intervention": "CYP substrates" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 31, "total_pages": 4, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=CYP+substrates&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-04T03:22:10.460Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03333824", "title": "Effects of AZD1775 on the PK Substrates for CYP3A, CYP2C19, CYP1A2 and on QT Interval in Patients With Advanced Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumours" ], "interventions": [ { "name": "CYP1A2 (caffeine)", "type": "DRUG" }, { "name": "CYP2C19 (omeprazole)", "type": "DRUG" }, { "name": "CYP3A (midazolam)", "type": "DRUG" }, { "name": "Kytril (granisetron)", "type": "DRUG" }, { "name": "Wee-1 kinase inhibitor AZD1775", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 33, "start_date": "2017-12-01", "completion_date": "2019-01-22", "has_results": false, "last_update_posted_date": "2019-03-25", "last_synced_at": "2026-09-04T03:22:10.460Z", "location_count": 7, "location_summary": "Bingham Farms, Michigan • Detroit, Michigan • Lebanon, New Hampshire + 4 more", "locations": [ { "city": "Bingham Farms", "state": "Michigan" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Lebanon", "state": "New Hampshire" }, { "city": "Cincinnati", "state": "Ohio" }, { "city": "Providence", "state": "Rhode Island" } ], "official_url": "https://clinicaltrials.gov/study/NCT03333824" }, { "nct_id": "NCT04254783", "title": "A Study to Evaluate the Effect of Intravenous (IV) Infusions of Risankizumab on Pharmacokinetics of Cytochome P450 Substrates in Adult Participants With Moderately to Severely Active Ulcerative Colitis or Crohn's Disease", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Ulcerative Colitis (UC)", "Crohn's Disease" ], "interventions": [ { "name": "Risankizumab", "type": "DRUG" }, { "name": "Cytochrome P450 (CYP) Substrates", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 20, "start_date": "2020-05-27", "completion_date": "2022-10-14", "has_results": false, "last_update_posted_date": "2024-07-01", "last_synced_at": "2026-09-04T03:22:10.460Z", "location_count": 4, "location_summary": "Coronado, California • DeLand, Florida • Margate, Florida + 1 more", "locations": [ { "city": "Coronado", "state": "California" }, { "city": "DeLand", "state": "Florida" }, { "city": "Margate", "state": "Florida" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04254783" }, { "nct_id": "NCT01473888", "title": "A Study To Evaluate The Effect of T89(Dantonic®)On P450 Enzymes", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Stable Angina" ], "interventions": [ { "name": "T89(Dantonic)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Tasly Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "50 Years", "sex": "ALL", "summary": "18 Years to 50 Years" }, "enrollment_count": 24, "start_date": "2011-01", "completion_date": "2012-01", "has_results": false, "last_update_posted_date": "2012-11-08", "last_synced_at": "2026-09-04T03:22:10.460Z", "location_count": 1, "location_summary": "Tacoma, Washington", "locations": [ { "city": "Tacoma", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT01473888" }, { "nct_id": "NCT07665723", "title": "An Early-Stage Study in Multiple Clinics of How Afimkibart May Affect the Body's Processing of Medicines That Rely on Cytochrome P450 Enzymes in Participants With Ulcerative Colitis", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Active Ulcerative Colitis" ], "interventions": [ { "name": "Afimkibart", "type": "DRUG" }, { "name": "Caffeine", "type": "DRUG" }, { "name": "Warfarin", "type": "DRUG" }, { "name": "Omeprazole", "type": "DRUG" }, { "name": "Dextromethorphan", "type": "DRUG" }, { "name": "Midazolam", "type": "DRUG" }, { "name": "Vitamin K", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "18 Years to 60 Years" }, "enrollment_count": 25, "start_date": "2026-06-29", "completion_date": "2030-12-31", "has_results": false, "last_update_posted_date": "2026-08-20", "last_synced_at": "2026-09-04T03:22:10.460Z", "location_count": 3, "location_summary": "Chula Vista, California • Miami, Florida", "locations": [ { "city": "Chula Vista", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT07665723" }, { "nct_id": "NCT07389525", "title": "Immune Checkpoint Inhibitor (ICI)-Drug-Drug Interaction (DDI) Study", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Gastrointestinal Neoplasms", "Genitourinary Cancer", "Thoracic Cancer", "Sarcoma", "Melanoma" ], "interventions": [ { "name": "ICI Therapy", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Indiana University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 80, "start_date": "2026-09", "completion_date": "2027-12", "has_results": false, "last_update_posted_date": "2026-07-15", "last_synced_at": "2026-09-04T03:22:10.460Z", "location_count": 1, "location_summary": "Indianapolis, Indiana", "locations": [ { "city": "Indianapolis", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT07389525" }, { "nct_id": "NCT04713254", "title": "Drug Drug Interaction Study With Lu AG06466 in Young Healthy Men", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "Lu AG06466", "type": "DRUG" }, { "name": "Midazolam", "type": "OTHER" }, { "name": "Metoprolol", "type": "OTHER" }, { "name": "Bupropion", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "H. Lundbeck A/S", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "45 Years", "sex": "ALL", "summary": "18 Years to 45 Years" }, "enrollment_count": 15, "start_date": "2020-12-08", "completion_date": "2021-04-09", "has_results": false, "last_update_posted_date": "2021-04-20", "last_synced_at": "2026-09-04T03:22:10.460Z", "location_count": 1, "location_summary": "Dallas, Texas", "locations": [ { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04713254" }, { "nct_id": "NCT07339722", "title": "A Study of LY4515100 in Healthy Participants", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "LY4515100 via SAD", "type": "DRUG" }, { "name": "LY4515100 via MAD", "type": "DRUG" }, { "name": "LY4515100", "type": "DRUG" }, { "name": "Itraconazole", "type": "DRUG" }, { "name": "Caffeine", "type": "DRUG" }, { "name": "Digoxin", "type": "DRUG" }, { "name": "Iohexol", "type": "DRUG" }, { "name": "Metformin", "type": "DRUG" }, { "name": "Rosuvastatin", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 123, "start_date": "2026-01-15", "completion_date": "2027-03", "has_results": false, "last_update_posted_date": "2026-07-29", "last_synced_at": "2026-09-04T03:22:10.460Z", "location_count": 1, "location_summary": "Dallas, Texas", "locations": [ { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT07339722" }, { "nct_id": "NCT07710768", "title": "A Research Study on How UBT251 Affects Levels of Midazolam, Caffeine and Warfarin in the Blood of Participants With Excess Body Weight", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Obesity", "Overweight" ], "interventions": [ { "name": "UBT251", "type": "DRUG" }, { "name": "Cocktail (Warfarin/Caffeine/Midazolam)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novo Nordisk A/S", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 44, "start_date": "2026-07-15", "completion_date": "2027-04-07", "has_results": false, "last_update_posted_date": "2026-08-18", "last_synced_at": "2026-09-04T03:22:10.460Z", "location_count": 1, "location_summary": "Cypress, California", "locations": [ { "city": "Cypress", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07710768" }, { "nct_id": "NCT05967689", "title": "A Study of Zipalertinib in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions or Other Uncommon Mutation.", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Advanced or Metastatic NSCLC Harboring Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion (ex20ins) Mutations" ], "interventions": [ { "name": "TAS6417", "type": "DRUG" }, { "name": "CYP Cocktail", "type": "DRUG" }, { "name": "Transporter Cocktail", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Taiho Oncology, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 220, "start_date": "2023-07-31", "completion_date": "2028-12-31", "has_results": false, "last_update_posted_date": "2026-09-01", "last_synced_at": "2026-09-04T03:22:10.460Z", "location_count": 18, "location_summary": "Birmingham, Alabama • Duarte, California • Boston, Massachusetts + 15 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Duarte", "state": "California" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Las Vegas", "state": "Nevada" }, { "city": "Basking Ridge", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT05967689" }, { "nct_id": "NCT05175352", "title": "A Study Evaluating Potential Disease-Mediated Drug-Drug Interaction in Adult Participants With Active Eosinophilic Esophagitis Receiving Cendakimab", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Eosinophilic Esophagitis" ], "interventions": [ { "name": "Cendakimab", "type": "DRUG" }, { "name": "CYP substrates", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Celgene", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 16, "start_date": "2022-06-07", "completion_date": "2024-10-11", "has_results": false, "last_update_posted_date": "2024-12-20", "last_synced_at": "2026-09-04T03:22:10.460Z", "location_count": 12, "location_summary": "Tucson, Arizona • Los Angeles, California • San Diego, California + 9 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Bristol", "state": "Connecticut" }, { "city": "Inverness", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05175352" } ] }